About us

Most business plans answer the question investors aren't asking.

Many business plans never make it from the analyst's desk into serious due diligence. The ones that do meet hard questions.

The natural response is to make the plan bigger: a larger market, higher prices, better margins, lower costs.

But that answers the upside question. Investors are just as focused on the downside: can this company protect what it builds, and defend its position long enough for them to earn a return?

Have you built real barriers to entry?
Do you own a niche others won't enter?
Can you lead your segment until your investors exit?

Leaders exit well. The fifth player in a category often struggles to exit at all.

Behind every tough diligence question is a simple one: is this the category leader, or the fifth player?

What we do

Steer by AmethIntel tests your plan the way investors will, and then to strengthen it.

Readiness Diagnostic

Built from our experience and input from our network, it shows how your company, or any venture, stacks up in an investor's view.

Start with a Readiness Diagnostic

Investor Questions

What you'll be asked, what a strong answer shows, and the red flags to avoid, so your answers are ready before the questions are.

See what investors will ask

Who we are

Steer by AmethIntel Distributed by Hb-022.

Based in Austin, Texas. We prepare science-led companies for Series A.

AmethIntel

the commercial intelligence platform. It runs on public and licensed market data.

Principals.

Akash Mathur, PhD, MBA

Co-founder

Akash has spent about 25 years in pharma and biotech business development, across licensing, deal structuring, competitive intelligence and clinical development. He has co-founded six startups in several countries, with several exits. His first, a protein multiplexing diagnostics platform, was acquired after successful pilot studies in academic labs. He advises on cross-border transactions in the India–US and Europe–India corridors, and has worked on regulatory and IP strategy across the US, Canada, Australia, Europe and India. He built AmethIntel. He holds a doctorate in human pathology from Saint Louis University and an MBA from the Olin School of Business, and taught MBA students for 13 years.

Gregory Schneider, PhD

Co-founder

Greg is a scientist whose career has centred on oncology: its biology, immunology and therapeutic approaches. After a PhD at Saint Louis University and postdoctoral training at the National Cancer Institute, he moved into supporting the pharmaceutical industry, working as the link between R&D, marketing and sales to position scientific products. His scientific messaging, and his training of client and technical-sales teams, have helped clients grow their sales. He is known for building trust with the research community.

What we don't do

We don't raise funds. We prepare companies to raise.

With a founder's written consent, we may introduce well-prepared companies to investors we know. We charge no fee for introductions.

We work under NDA, and we delete your confidential information once your deliverable is final. See our Privacy policy.

Where would your company stand?

Start with a Readiness Diagnostic See what investors will ask →